1. Colircusi Tropicamida
2. Minims Tropicamide
3. Mydral
4. Mydriafair
5. Mydriaticum
6. Mydrum
7. N-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)benzeneacetamide
8. N-ethyl-n-(4-pyridylmethyl)tropamide
9. Ocu Tropic
10. Ocu-tropic
11. Ocutropic
12. Tropicacyl
13. Tropicamide Faure
14. Tropicamide Minims
15. Tropicamide Monofree
16. Tropicamide Monohydrochloride, (r)-isomer
17. Tropicamide Monohydrochloride, (s)-isomer
18. Tropicamide, (+-)-isomer
19. Tropicamide, (r)-isomer
20. Tropicamide, (s)-isomer
1. 1508-75-4
2. Mydriacyl
3. Mydriaticum
4. Bistropamide
5. Tropicacyl
6. Visumidriatic
7. N-ethyl-3-hydroxy-2-phenyl-n-(pyridin-4-ylmethyl)propanamide
8. Tropicamidum
9. Ro 1-7683
10. N-ethyl-2-phenyl-n-(4-pyridylmethyl)hydracrylamide
11. Mydriafair
12. Minims Tropicamide
13. Epitromina
14. Tropikamid
15. Mydrum
16. Nsc-757372
17. N0a3z5xtc6
18. Tropimil
19. Ncgc00016065-07
20. Tropicamida
21. Ro-1-7683
22. Benzeneacetamide, N-ethyl-.alpha.-(hydroxymethyl)-n-(4-pyridinylmethyl)-
23. Dsstox_cid_25220
24. Dsstox_rid_80757
25. Dsstox_gsid_45220
26. Tropicamidum [inn-latin]
27. Tropicamida [inn-spanish]
28. Tropicamid
29. Mydriacyl (tn)
30. N-ethyl-n-(4-pyridylmethyl)tropamid
31. N-ethyl-n-(4-pyridylmethyl)tropamide
32. Smr000058523
33. Sr-01000075351
34. Einecs 216-140-2
35. Unii-n0a3z5xtc6
36. N-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)benzeneacetamide
37. Brn 0285563
38. Tropicamide, Solid
39. Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)-
40. Prestwick_487
41. Cas-1508-75-4
42. Component Of Paremyd
43. Mfcd00058580
44. Hydracrylamide, N-ethyl-2-phenyl-n-(4-pyridylmethyl)-
45. Tropicamide [usan:usp:inn:ban:jan]
46. (+-)-n-ethyl-2-phenyl-n-(4-pyridylmethyl)hydracrylamide
47. Spectrum_000584
48. Tropicamide [mi]
49. Prestwick0_000228
50. Prestwick1_000228
51. Prestwick2_000228
52. Prestwick3_000228
53. Spectrum2_000936
54. Spectrum3_000655
55. Spectrum4_000377
56. Spectrum5_001585
57. Tropicamide [inn]
58. Tropicamide [jan]
59. Tropicamide [usan]
60. T 9778
61. Tropicamide [vandf]
62. Tropicamide [mart.]
63. Lopac0_001223
64. Schembl23975
65. Bspbio_000275
66. Bspbio_002289
67. Kbiogr_000873
68. Kbioss_001064
69. Tropicamide [usp-rs]
70. Tropicamide [who-dd]
71. Tropicamide [who-ip]
72. 5-22-09-00359 (beilstein Handbook Reference)
73. Mls001306442
74. Mls002154240
75. Divk1c_000448
76. Spectrum1500599
77. Spbio_000872
78. Spbio_002196
79. Bpbio1_000303
80. Chebi:9757
81. Gtpl7319
82. Tropicamide (jp17/usp/inn)
83. Chembl1200604
84. Dtxsid8045220
85. Bdbm82371
86. Hms501g10
87. Kbio1_000448
88. Kbio2_001064
89. Kbio2_003632
90. Kbio2_006200
91. Kbio3_001509
92. Tropicamide [orange Book]
93. Ninds_000448
94. Hms1568n17
95. Hms1921i09
96. Hms2089m05
97. Hms2092a18
98. Hms2095n17
99. Hms2235j15
100. Hms3259m18
101. Hms3263f08
102. Hms3267a13
103. Hms3373b07
104. Hms3411f14
105. Hms3651k04
106. Hms3675f14
107. Hms3712n17
108. Hms3742c05
109. Hms3884e16
110. Pharmakon1600-01500599
111. Tropicamide [ep Monograph]
112. Tropicamide For Peak Identification
113. Tropicamide [usp Monograph]
114. Bcp13504
115. Hy-b0321
116. Nsc_5593
117. Paremyd Component Tropicamide
118. Tropicamidum [who-ip Latin]
119. Tox21_110297
120. Tox21_501223
121. Ac-816
122. Bbl028074
123. Ccg-40076
124. Nsc757372
125. S1913
126. Stk934612
127. Akos005664076
128. Tox21_110297_1
129. Am84467
130. Db00809
131. Ks-5174
132. Lp01223
133. Nc00589
134. Nsc 757372
135. Sdccgsbi-0051190.p004
136. Tropicamide Component Of Paremyd
137. Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)-, (+-)-
138. Idi1_000448
139. Smp1_000304
140. Ncgc00016065-03
141. Ncgc00016065-04
142. Ncgc00016065-05
143. Ncgc00016065-06
144. Ncgc00016065-08
145. Ncgc00016065-09
146. Ncgc00016065-11
147. Ncgc00016065-22
148. Ncgc00024866-02
149. Ncgc00024866-03
150. Ncgc00024866-04
151. Ncgc00024866-05
152. Ncgc00024866-06
153. Ncgc00261908-01
154. Cas_1508-75-4
155. Sbi-0051190.p003
156. Ab00052120
157. Eu-0101223
158. Ft-0657590
159. Sw196691-3
160. T1470
161. C72868
162. D00397
163. Q29310
164. Ab00052120-10
165. Ab00052120_11
166. Ab00052120_12
167. 508t754
168. L001262
169. N-ethyl-2-phenyl-n-(4-pyridylmethyl Hydracrylamide
170. Q-201902
171. Sr-01000075351-1
172. Sr-01000075351-3
173. Sr-01000075351-5
174. Sr-01000075351-7
175. Brd-a79672927-001-05-8
176. Brd-a79672927-001-10-8
177. Tropicamide, European Pharmacopoeia (ep) Reference Standard
178. N-ethyl-3-hydroxy-2-phenyl-n-(4-pyridinylmethyl)propanamide #
179. (+/-)-n-ethyl-2-phenyl-n-(4-pyridylmethyl)hydracrylamide
180. Tropicamide, United States Pharmacopeia (usp) Reference Standard
181. Benzeneacetamide, N-ethyl-.alpha.-(hydroxymethyl)-n-(4-pyridinylmethyl)-, (+/-)-
182. Tropicamide For Peak Identification, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 284.35 g/mol |
|---|---|
| Molecular Formula | C17H20N2O2 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 284.152477885 g/mol |
| Monoisotopic Mass | 284.152477885 g/mol |
| Topological Polar Surface Area | 53.4 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 310 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 8 | |
|---|---|
| Drug Name | Mydriacyl |
| PubMed Health | Atropine, Homatropine, and Scopolamine (Ophthalmic route) |
| Drug Classes | Mydriatic-Cycloplegic |
| Drug Label | MYDRIACYL (tropicamide ophthalmic solution, USP) is an anticholinergic prepared as a sterile topical ophthalmic solution in two strengths. The active ingredient is represented by the chemical structure:Each mL contains: Active: tropicamide 0.5% or... |
| Active Ingredient | Tropicamide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 1% |
| Market Status | Prescription |
| Company | Alcon |
| 2 of 8 | |
|---|---|
| Drug Name | Paremyd |
| PubMed Health | Tropicamide (Into the eye) |
| Active Ingredient | tropicamide; Hydroxyamphetamine hydrobromide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 1%; 0.25% |
| Market Status | Prescription |
| Company | Akorn |
| 3 of 8 | |
|---|---|
| Drug Name | Tropicacyl |
| Drug Label | MYDRIACYL (tropicamide ophthalmic solution, USP) is an anticholinergic prepared as a sterile topical ophthalmic solution in two strengths. The active ingredient is represented by the chemical structure:Each mL contains: Active: tropicamide 0.5% or... |
| Active Ingredient | Tropicamide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 1% |
| Market Status | Prescription |
| Company | Akorn |
| 4 of 8 | |
|---|---|
| Drug Name | Tropicamide |
| Active Ingredient | Tropicamide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 1% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
| 5 of 8 | |
|---|---|
| Drug Name | Mydriacyl |
| PubMed Health | Atropine, Homatropine, and Scopolamine (Ophthalmic route) |
| Drug Classes | Mydriatic-Cycloplegic |
| Drug Label | MYDRIACYL (tropicamide ophthalmic solution, USP) is an anticholinergic prepared as a sterile topical ophthalmic solution in two strengths. The active ingredient is represented by the chemical structure:Each mL contains: Active: tropicamide 0.5% or... |
| Active Ingredient | Tropicamide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 1% |
| Market Status | Prescription |
| Company | Alcon |
| 6 of 8 | |
|---|---|
| Drug Name | Paremyd |
| PubMed Health | Tropicamide (Into the eye) |
| Active Ingredient | tropicamide; Hydroxyamphetamine hydrobromide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 1%; 0.25% |
| Market Status | Prescription |
| Company | Akorn |
| 7 of 8 | |
|---|---|
| Drug Name | Tropicacyl |
| Drug Label | MYDRIACYL (tropicamide ophthalmic solution, USP) is an anticholinergic prepared as a sterile topical ophthalmic solution in two strengths. The active ingredient is represented by the chemical structure:Each mL contains: Active: tropicamide 0.5% or... |
| Active Ingredient | Tropicamide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 1% |
| Market Status | Prescription |
| Company | Akorn |
| 8 of 8 | |
|---|---|
| Drug Name | Tropicamide |
| Active Ingredient | Tropicamide |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 1% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
Tropicamide is indicated to induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures. It is used in combination with [hydroxyamphetamine] for the same indication.
Tropicamide is an anticholinergic drug and that works by nonselectively blocking muscarinic receptors to cause mydriasis and cycloplegia. It relaxes the pupillary sphincter to dilate the pupil. The onset of tropicamideinduced mydriasis is about 10 to 15 minutes, with optimal effect occurring 25 to 30 minutes post-administration. Mydriasis caused by tropicamide wears off within four to eight hours, but it was seen up to 24 hours in some individuals. Tropicamide causes accommodation by causing contraction of the ciliary muscle. The cycloplegic effect occurs within 20 to minutes following administration, with a duration of action of four to 10 hours. Tropicamide can elevate intraocular pressure. The ophthalmic use of tropicamide is not typically associated with serious systemic adverse events. One randomized pilot study showed that oral tropicamide alleviated perceived symptoms of sialorrhea in patients with Parkinson's Disease: anticholinergics are believed to restore the dopaminergic to cholinergic activity imbalance in neurodegenerative diseases. Similarly in one case report, tropicamide administered via ophthalmic solution relieved clozapine-induced sialorrhea. Interestingly, in rodent models, tropicamide suppressed drug-induced tremulous jaw movements which are often used as a model of parkinsonian tremor: the significance of this finding requires further investigations.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Mydriatics
Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)
S01FA06
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01F - Mydriatics and cycloplegics
S01FA - Anticholinergics
S01FA06 - Tropicamide
Absorption
Following ocular administration of 40 L drops of 0.5% tropicamide in female subjects, tropicamide reached its mean peak concentration in plasma of 2.8 1.7 ng/mL (mean SD) at five minutes.
Route of Elimination
No information can be found.
Volume of Distribution
No information can be found.
Clearance
No information can be found.
No information can be found.
Tropicamide has a plasma half-life of 30minutes.
Muscarinic acetylcholine receptors are involved in numerous ocular functions. The M3 subtype is predominantly expressed by smooth muscle cells of the sphincter pupillae, which is a circular muscle of the iris, and ciliary muscles. In response to light or binding of acetylcholine, M3 receptor signalling leads to contraction of the sphincter pupillae and pupil constriction. Contraction of the ciliary muscle via M3 receptor signalling also leads to accommodation, adjusting the lens for near vision. The eye is also innervated by parasympathetic nerves: ciliary ganglion neurons project to the ciliary body and the sphincter pupillae muscle of the iris to control ocular accommodation and pupil constriction. Tropicamide is a non-selective muscarinic antagonist that binds to all subtypes of muscarinic receptors. By binding to muscarinic receptors, tropicamide relaxes the pupillary sphincter muscle and causes pupil dilation. By blocking the muscarinic receptors of the ciliary body, tropicamide also prevents accommodation. Like other muscarinic antagonists, tropicamide inhibits the parasympathetic drive, allowing the sympathetic nervous system responses to dominate. Tropicamide is thought to ameliorate sialorrhea by blocking M4 receptors expressed on salivary glands and reducing hypersalivation.
LOOKING FOR A SUPPLIER?
